AstraZeneca is considering its legal options after the Federal Court of Australia revoked a number of patents for its blockbuster drug Crestor (rosuvastatin).
The decision handed down today paves the way for generic brands of the drug to enter the market.
A spokesperson for AstraZeneca told Pharmacy News the company was “disappointed” by the Court’s decision.
“AstraZeneca Australia is disappointed with the Court’s decision in relation to some of its patents for Crestor (rosuvastatin) in Australia,” the spokesperson said.
“We are analysing the Court’s written decision and over the coming days we will be considering our legal options, including whether to file an appeal.”
For more on this see PharmacyNews.com.au or our daily newsletter tomorrow.
The decision handed down today paves the way for generic brands of the drug to enter the market.
A spokesperson for AstraZeneca told Pharmacy News the company was “disappointed” by the Court’s decision.
“AstraZeneca Australia is disappointed with the Court’s decision in relation to some of its patents for Crestor (rosuvastatin) in Australia,” the spokesperson said.
“We are analysing the Court’s written decision and over the coming days we will be considering our legal options, including whether to file an appeal.”
For more on this see PharmacyNews.com.au or our daily newsletter tomorrow.